Tonix Pharmaceuticals Holding Corp. (TNXP) › Operating IncomeTonix Pharmaceuticals Holding Corp. (TNXP) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2010: -$1.93M2011: -$3.38M2012: -$6.66M2013: -$10.89M2014: -$27.66M2015: -$48.16M2016: -$38.97M2017: -$21.29M2018: -$26.32M2019: -$28.83M2020: -$50.51M2021: -$92.31M2022: -$112.09M2023: -$118.38M2024: -$136.70M2025: -$125.70M-$125.70M2010Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$125.70M+8.0%2024-$136.70M-15.5%2023-$118.38M-5.6%2022-$112.09M-21.4%2021-$92.31M-82.8%2020-$50.51M-75.2%2019-$28.83M-9.5%2018-$26.32M-23.6%2017-$21.29M+45.4%2016-$38.97M+19.1%2015-$48.16M-74.1%2014-$27.66M-154.0%2013-$10.89M-63.4%2012-$6.66M-97.2%2011-$3.38M-75.2%2010-$1.93M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share